Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lisata Therapeutics, Inc. - Common Stock
(NQ:
LSTA
)
3.340
-0.170 (-4.84%)
Streaming Delayed Price
Updated: 3:55 PM EDT, Jul 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,910
Open
3.440
Bid (Size)
3.340 (3)
Ask (Size)
3.480 (3)
Prev. Close
3.510
Today's Range
3.340 - 3.515
52wk Range
1.950 - 3.870
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
June 13, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
May 28, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
+20.14%
+20.14%
1 Month
-3.19%
-3.19%
3 Month
+14.78%
+14.78%
6 Month
+8.79%
+8.79%
1 Year
-7.99%
-7.99%
More News
Read More
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
May 20, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
May 13, 2024
Via
News Direct
Exposures
Product Safety
Recap: Lisata Therapeutics Q4 Earnings
February 29, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
February 29, 2024
Via
Benzinga
Lisata Therapeutics's Earnings Outlook
February 28, 2024
Via
Benzinga
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
May 13, 2024
Via
TheNewswire.com
Exposures
Product Safety
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q1 2024
May 09, 2024
Via
InvestorPlace
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
May 08, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
May 02, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
April 23, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
April 09, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
April 03, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
March 21, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
March 08, 2024
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
March 05, 2024
From
Virtual Investor Conferences
Via
GlobeNewswire
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ
March 04, 2024
From
Virtual Investor Conferences
Via
GlobeNewswire
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
February 29, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
February 22, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Present at BIO CEO & Investor Conference
February 20, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme
January 17, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
January 04, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
December 12, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.